Fingolimod Administered Orally Once Daily vs Interferon Beta-1a i.m. Once Weekly in Pediatric Patients with Multiple Sclerosis
-
Sponsor: Novartis Pharma AG
Location(s): United States
Description
PARADIGMS is a 24-month research study intended to see if an FDA-approved oral disease modifying treatment (DMT) for adult patients can help children with MS.